The Withdrawal of Drugs for Commercial Reasons
This Viewpoint uses manufacturer withdrawal of tositumomab as an illustration of deficiencies in current standards of drug development and post-marketing evaluation.
Source: JAMA Oncology - Category: Cancer & Oncology Authors: Vinay Prasad, MD Tags: Featured Opinion JAMA Internal Medicine Viewpoint Source Type: research